Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504852 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
A Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 331
- Enrollment target
- 20
- Study locations
NCT03504852: Completed Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis, sponsored by Novartis Pharmaceuticals.
NCT03504852 is a Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 331 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03504852, a Phase 3 study of Moderate to Severe Chronic Plaque-Type Psoriasis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 331 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
Primary Outcome
A subject was considered as a PASI 90 responder if s/he achieved a reduction of 90% or more of the PASI score, compared to baseline, at a given time point.The head, trunk, upper limbs and lower limbs were assessed separately for erythema, thickening, and scaling. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0, i.e., higher scores represent more severity.
Conditions Studied
Interventions
- DRUG secukinumab 150 mg
Study Locations (20)
California
- Novartis Investigative Site - Irvine
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - San Diego
- Novartis Investigative Site - Santa Monica
Florida
- Novartis Investigative Site - Tampa
- Novartis Investigative Site - West Palm Beach
Georgia
- Novartis Investigative Site - Alpharetta
- Novartis Investigative Site - Snellville
Indiana
- Novartis Investigative Site - Indianapolis
- Novartis Investigative Site - New Albany
Kentucky
- Novartis Investigative Site - Louisville
- Novartis Investigative Site - Owensboro
Alabama
- Novartis Investigative Site - Birmingham
Arizona
- Novartis Investigative Site - Phoenix
Arkansas
- Novartis Investigative Site - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2018-06-25 |
| Est. Completion | 2020-07-15 |
| Phase | Phase 3 |
What the finished NCT03504852 record still lists
NCT03504852 is an interventional study that assigns participants to a tested intervention. The registered 331 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Moderate to Severe Chronic Plaque-Type Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which secukinumab 150 mg is the first listed.
NCT03504852 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT03504852 about?
NCT03504852 is a clinical study titled "Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis". The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT03504852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 331 participants. The study started on 2018-06-25. Estimated completion is 2020-07-15.
What conditions does trial NCT03504852 study?
This clinical trial studies the following conditions: Moderate to Severe Chronic Plaque-Type Psoriasis.
What interventions are being tested in trial NCT03504852?
The interventions under investigation include: secukinumab 150 mg (DRUG).
Who is sponsoring clinical trial NCT03504852?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03504852 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Chronic Plaque-Type Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03504852's enrollment target sits among peer trials
331 1066th of 2000 higher than 935 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI